1bln
From Proteopedia
| Line 1: | Line 1: | ||
[[Image:1bln.gif|left|200px]] | [[Image:1bln.gif|left|200px]] | ||
| - | + | <!-- | |
| - | + | The line below this paragraph, containing "STRUCTURE_1bln", creates the "Structure Box" on the page. | |
| - | + | You may change the PDB parameter (which sets the PDB file loaded into the applet) | |
| - | | | + | or the SCENE parameter (which sets the initial scene displayed when the page is loaded), |
| - | | | + | or leave the SCENE parameter empty for the default display. |
| - | + | --> | |
| - | + | {{STRUCTURE_1bln| PDB=1bln | SCENE= }} | |
| - | + | ||
| - | + | ||
| - | }} | + | |
'''ANTI-P-GLYCOPROTEIN FAB MRK-16''' | '''ANTI-P-GLYCOPROTEIN FAB MRK-16''' | ||
| Line 19: | Line 16: | ||
==About this Structure== | ==About this Structure== | ||
| - | + | Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=1BLN OCA]. | |
==Reference== | ==Reference== | ||
Mode of binding of anti-P-glycoprotein antibody MRK-16 to its antigen. A crystallographic and molecular modeling study., Vasudevan S, Tsuruo T, Rose DR, J Biol Chem. 1998 Sep 25;273(39):25413-9. PMID:[http://www.ncbi.nlm.nih.gov/pubmed/9738009 9738009] | Mode of binding of anti-P-glycoprotein antibody MRK-16 to its antigen. A crystallographic and molecular modeling study., Vasudevan S, Tsuruo T, Rose DR, J Biol Chem. 1998 Sep 25;273(39):25413-9. PMID:[http://www.ncbi.nlm.nih.gov/pubmed/9738009 9738009] | ||
| - | [[Category: Mus musculus]] | ||
| - | [[Category: Protein complex]] | ||
[[Category: Rose, D R.]] | [[Category: Rose, D R.]] | ||
[[Category: Tsuruo, T.]] | [[Category: Tsuruo, T.]] | ||
[[Category: Vasudevan, S.]] | [[Category: Vasudevan, S.]] | ||
| - | [[Category: | + | [[Category: Immunoglobulin]] |
| - | + | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Fri May 2 11:40:27 2008'' | |
| - | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on | + | |
Revision as of 08:40, 2 May 2008
ANTI-P-GLYCOPROTEIN FAB MRK-16
Overview
Monoclonal antibody MRK-16 recognizes a discontinuous extracellular epitope on the multidrug resistance-associated ATP-binding cassette transporter, P-glycoprotein. The atomic basis for specificity of this antibody is of interest because of its potential as a modulator of P-glycoprotein activity. The crystal structure of Fab MRK-16 is reported to a resolution of 2.8 A. A structure for a portion of the epitope was derived by comparison to regions of solved structures with similar primary sequence. This has permitted a proposal for the mode of binding of the peptide epitope to the antibody, in which the peptide makes specific contacts with complementarity-determining regions H1, H2, and H3 from the heavy chain and L3 from the light chain. These interactions are consistent with epitope mapping studies and with the observation that MRK-16 is specific for human class I P-glycoprotein. This result identifies side chains in MRK-16 that would be amenable to alteration in antibody engineering experiments to derive improved multidrug resistance inhibitors for clinical use during chemotherapy. In particular, Arg-H97 contacts both Glu-746 and Asp-744 of the peptide, Arg-L96 contacts Asp-743, and Thr-H33 interacts with Thr-747. All of these epitope residues were implicated in mediating specificity by epitope mapping studies.
About this Structure
Full crystallographic information is available from OCA.
Reference
Mode of binding of anti-P-glycoprotein antibody MRK-16 to its antigen. A crystallographic and molecular modeling study., Vasudevan S, Tsuruo T, Rose DR, J Biol Chem. 1998 Sep 25;273(39):25413-9. PMID:9738009 Page seeded by OCA on Fri May 2 11:40:27 2008
